secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001683168-23-003312
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma Q1 net loss $4.9M; Berubicin interim analysis on track for Q3 2023
-----------------------------------------------------------------------------

- Net loss $4.9M vs $3.2M YoY; R&D expense $3.6M (+$1.7M) driven by CRO costs for Berubicin trial.
- Cash $5.1M at Mar 31; subsequent ATM raised ~$2.0M (avg $3.08/share) and ~$0.7M from warrant exercises.
- Enrollment >100 patients in potentially pivotal Berubicin GBM trial; 45 of 60 sites open across US and Europe.
- Interim analysis results expected Q3 2023; topline data after enrollment complete.
- Appointed Dr. Bettina Cockroft and Faith Charles to Board, strengthening biopharma and governance expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823003312/0001683168-23-003312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823003312/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer